Composite Materials with Combined Electronic and Ionic Properties

In this work, we develop a new type of composite material that combines both electrocatalytic and ionic properties, by doping a silver metal catalyst with an anion-conducting ionomer at the molecular level. We show that ionomer entrapment into the silver metallic structure is possible, imparting unique properties to the catalytic character of the metallic silver. The novel composite material is tested as the cathode electrode of fuel cells, showing significant improvement in cell performance as compared with the undoped counterpart. This new type of material may then replace the current design of electrodes in advanced fuel cells or other electrochemical devices. The possibility to merge different properties into one composite material by molecular entrapment in metals can open the way to new materials, leading to unexplored fields and applications

The Properties of X-Ray and Optical Light Curves of X-Ray Novae

We have collected the available data from the literature and from public data archives covering the past two decades for the long-term X-ray and optical light curves of X-ray nova (XN) outbursts, and carry out for the first time a systematic, statistical study of XN light curves which are classified into 5 morphological types. Basic light curve parameters, e.g., the outburst peak flux, amplitude, luminosity, rise and decay timescales, the observed and expected outburst durations, and total energy radiated, are tabulated and discussed. The rise timescales are found to have a flat distribution while the decay timescales have a much narrower and near-Gaussian distribution, centered around 30 days and dominated by the strongest outbursts. The peak luminosity is also distributed like a Gaussian, centered around 0.2 in Eddington units, while the total energy released has a much broader distribution around 10E44 ergs. We identify and discuss additional light curve features, such as precursors, plateaus, and secondary maxima. The plateaus exhibited in the light curves of black hole sources are found to have, on average, longer durations and they are followed by longer decays. The identified secondary maxima seem to occur mostly in black hole systems. For the frequency of outbursts, we find that the average XN outburst rate is about 2.6 per year for events >0.3 Crab, and that the mean recurrence time between outbursts from a single source is 6 years. The spatial and logN-logS distribution of the XN sources, with limited statistics, agrees with a source population in the Galactic disk, as observed from a point at a distance of 8.5 kpc from the Galactic center. Finally, we point out that the observed XN light curve properties can in general be explained by a disk thermal instability model, although some important problems still remain.Comment: 68 pages including 27 Postscript figures and 12 tables. To be published in the Astrophysical Journal, Part

Hypertonic Stress Induces VEGF Production in Human Colon Cancer Cell Line Caco-2: Inhibitory Role of Autocrine PGE2

Vascular Endothelial Growth Factor (VEGF) is a major regulator of angiogenesis. VEGF expression is up regulated in response to micro-environmental cues related to poor blood supply such as hypoxia. However, regulation of VEGF expression in cancer cells is not limited to the stress response due to increased volume of the tumor mass. Lipid mediators in particular arachidonic acid-derived prostaglandin (PG)E2 are regulators of VEGF expression and angiogenesis in colon cancer. In addition, increased osmolarity that is generated during colonic water absorption and feces consolidation seems to activate colon cancer cells and promote PGE2 generation. Such physiological stimulation may provide signaling for cancer promotion. Here we investigated the effect of exposure to a hypertonic medium, to emulate colonic environment, on VEGF production by colon cancer cells. The role of concomitant PGE2 generation and MAPK activation was addressed by specific pharmacological inhibition. Human colon cancer cell line Caco-2 exposed to a hypertonic environment responded with marked VEGF and PGE2 production. VEGF production was inhibited by selective inhibitors of ERK 1/2 and p38 MAPK pathways. To address the regulatory role of PGE2 on VEGF production, Caco-2 cells were treated with cPLA2 (ATK) and COX-2 (NS-398) inhibitors, that completely block PGE2 generation. The Caco-2 cells were also treated with a non selective PGE2 receptor antagonist. Each treatment significantly increased the hypertonic stress-induced VEGF production. Moreover, addition of PGE2 or selective EP2 receptor agonist to activated Caco-2 cells inhibited VEGF production. The autocrine inhibitory role for PGE2 appears to be selective to hypertonic environment since VEGF production induced by exposure to CoCl2 was decreased by inhibition of concomitant PGE2 generation. Our results indicated that hypertonicity stimulates VEGF production in colon cancer cell lines. Also PGE2 plays an inhibitory role on VEGF production by Caco-2 cells exposed to hyperosmotic stress through EP2 activation

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Background: Sjögren's syndrome is an autoimmune disease characterised by dry eyes and mouth, systemic features, and reduced quality of life. There are no disease-modifying treatments. A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy. This dose-finding trial aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren's syndrome. Methods: VAY736A2201 was a randomised, parallel, double-blind, placebo-controlled, phase 2b dose-finding study done in 56 centres in 19 countries. Patients aged 18–75 years with primary Sjögren's syndrome with moderate to severe disease activity (European Alliance of Associations for Rheumatology [EULAR] Sjögren's Syndrome Disease Activity Index [ESSDAI] score ≥6) and symptom severity (EULAR Sjögren's Syndrome Patient Reported Index score ≥5) were eligible. Participants were randomly assigned (1:1:1:1) to receive subcutaneous placebo or ianalumab (5 mg, 50 mg, or 300 mg) every 4 weeks for 24 weeks using a secure, online randomisation system. Randomisation was stratified by the ESSDAI score at baseline (≥10 or <10). Study personnel and patients were masked to treatment assignment. The primary outcome was the change in ESSDAI score from baseline to 24 weeks in all randomly assigned patients. Dose-related change in disease activity (ESSDAI) from baseline at week 24 was assessed by multiple comparison procedure with modelling analysis. Safety was measured in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT02962895. Findings: Between June 27, 2017, and Dec 06, 2018, 293 patients were screened, 190 of whom were randomly assigned (placebo n=49, ianalumab 5 mg n=47, ianalumab 50 mg n=47, ianalumab 300 mg n=47). Statistically significant dose-responses were seen for overall disease activity (ESSDAI score) in four of the five dose-response models tested (p<0·025 in four models, p=0·060 in one model). The ESSDAI score decreased from baseline in all ianalumab groups, with the maximal ESSDAI score change from baseline observed in the ianalumab 300 mg group: placebo-adjusted least-squares mean change from baseline −1·92 points (95% CI −4·15 to 0·32; p=0·092). There were four serious adverse events in three patients considered treatment-related (pneumonia [n=1] and gastroenteritis [n=1] in the placebo group; appendicitis plus tubo-ovarian abscess in the same patient in the ianalumab 50 mg group). Interpretation: The study met its primary objective, showing a dose-related decrease in disease activity as measured by ESSDAI at week 24. Overall, ianalumab was well tolerated and safe, with no increase in infections. To our knowledge, this is the first large, randomised, controlled trial in primary Sjögren's syndrome that met its primary endpoint, and its results mean there is potential for more studies of this mechanism in the future. Funding: Novartis